drugset / Trial / NCT04527289

Impact of Amantadine on Traumatic Brain Injury

NCT04527289

Phase 4 Completed 50 enrolled Damanhour University
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to evaluate whether the addition of amantadine to the management regimen of traumatic brain injury patients would have a favorable effect on recovery and neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18), Neuron-specific enolase (NSE) and (Neurotensin).

Timeline

Start
2020-09-30
Primary completion
2021-10-01
Completion
2021-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 100 mg Oral